Karen Christman’s group makes strides toward clinical therapy
Both local NPR affiliate KPBS and the San Diego Union-Tribune covered CEN PI Karen Christman’s paper in the Journal of the American College of Cardiology. The paper reports her group’s success in translating their work on an injectable hydrogel as post-heart attack therapy into a large animal model. This hydrogel is derived from heart muscle, so it matches native nanostructure and contains biochemical cues that counteract the inflammatory response to heart attack damage. Further, it’s one of very few hydrogels designed to gel upon minimally invasive catheter injection; most would gel too quickly for this form of administration. Christman has founded a company, Ventrix, to move toward commercializing this technology (VentriGel) by organizing clinical trials.